Good morning, everyone, and welcome to another working week, albeit an abbreviated one on this side of the pond thanks to an extended weekend respite. Of course, this means a game of catchup with those of you located in other regions. So on that note, we are firing up the trusty coffee kettle and brewing cups of stimulation. Our choice today is cinnamon mocha. Yum. Meanwhile, we have assembled the usual menu of tidbits, although it does appear a bit quiet at the moment. No matter, this will not last long. Have a great day, and keep in touch. …
As Purdue Pharma attempts to win a controversial reorganization plan in bankruptcy court, the drug maker is also seeking approval for $34.7 million in employee bonuses, including $2.1 million for the chief executive officer, STAT reports. The request raises the possibility of yet another round of outrage over company bonuses. Currently, about 500 Purdue employees are eligible for bonuses, or $67,000 per person. By contrast, the reorganization plan sets a maximum payout of $48,000 to individual claimants.
A new report finds “notable gaps” in the quality and availability of clinical trial data in a European registry, pointing to inconsistent and often inadequate oversight by regulators in individual countries, STAT says. For instance, 1,207 trials were approved by regulators in France and 831 trials authorized by authorities in Poland but do not appear in the European Union Clinical Trials Register. About 90% of older trials were approved by regulators in The Netherlands, but results are not available. Nearly 6,000 study results are missing across 14 countries.
Create a display name to comment
This name will appear with your comment